We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

32 hedge funds and large institutions have $14.3M invested in PDS Biotechnology in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more capital invested

Capital invested by funds: $6.92M → $14.3M (+$7.39M)

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

7% more funds holding

Funds holding: 30 → 32 (+2)

0.01% less ownership

Funds ownership: 14.14% → 14.13% (-0.01%)

Holders
32
Holders Change
+2
Holders Change %
+6.67%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
9
Reduced
7
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$1.54M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$591K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$314K
4
Marshall Wace
Marshall Wace
United Kingdom
+$178K
5
BFM
Boothbay Fund Management
New York
+$173K

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$822K
2
Renaissance Technologies
Renaissance Technologies
New York
-$648K
3
BlackRock
BlackRock
New York
-$248K
4
UBS Group
UBS Group
Switzerland
-$224K
5
GAM
Gotham Asset Management
New York
-$219K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.92M +$591K +146,953 +21%
Renaissance Technologies
2
Renaissance Technologies
New York
$3.04M -$648K -160,974 -19%
IC
3
Ikarian Capital
Texas
$1.75M +$1.54M +383,373 New
IWA
4
Inspirion Wealth Advisors
Illinois
$1.13M +$39.8K +9,885 +4%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$774K +$314K +77,911 +84%
First Manhattan
6
First Manhattan
New York
$678K – – –
SI
7
Sofinnova Investments
California
$649K – – –
NLVP
8
New Leaf Venture Partners
New York
$533K – – –
MWM
9
Minot Wealth Management
Massachusetts
$207K -$15.1K -3,764 -8%
Marshall Wace
10
Marshall Wace
United Kingdom
$201K +$178K +44,232 New
BFM
11
Boothbay Fund Management
New York
$195K +$173K +42,937 New
BlackRock
12
BlackRock
New York
$194K -$248K -61,616 -59%
Northern Trust
13
Northern Trust
Illinois
$165K -$48.8K -12,124 -25%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$154K -$9.91K -2,463 -7%
AFM
15
Andesa Financial Management
Pennsylvania
$152K +$67K +16,655 +100%
TRCT
16
Tower Research Capital (TRC)
New York
$107K +$94.4K +23,447 New
Millennium Management
17
Millennium Management
New York
$96K +$85K +21,132 New
Goldman Sachs
18
Goldman Sachs
New York
$95K +$5.1K +1,267 +6%
LNC
19
Lincoln National Corp
Pennsylvania
$76K – – –
Cetera Investment Advisers
20
Cetera Investment Advisers
Illinois
$48K +$42.3K +10,500 New
VF
21
Virtu Financial
New York
$48K +$42.7K +10,602 New
EIP
22
Ellis Investment Partners
Pennsylvania
$35K -$40.6K -10,100 -57%
RE
23
RBC Europe
United Kingdom
$21.2K +$5.63K +1,400 +43%
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$18K +$16.1K +4,000 New
Morgan Stanley
25
Morgan Stanley
New York
$13K +$4.39K +1,090 +64%
1
2

PDSB Hedge Fund Activity: Q1 2021 in Review

32 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2021, worth a combined $14.3M — up 107% from $6.92M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new PDSB positions and 9 closed out — a net gain of 2 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.54M. The largest seller was Federated Hermes, exiting entirely with an estimated $822K sold.

  • 32 institutional investors held PDS Biotechnology (PDSB) as of Q1 2021, up from 30 in Q4 2020.
  • Funds reported $14.3M of PDS Biotechnology stock for Q1 2021, up 107% quarter-over-quarter.
  • 11 funds opened new PDS Biotechnology positions in Q1 2021 and 9 closed out, a net change of +2 holders.
  • The largest PDS Biotechnology buyer in Q1 2021 was Ikarian Capital, an estimated $1.54M added.
  • The largest PDS Biotechnology seller in Q1 2021 was Federated Hermes, an estimated $822K sold.

Based on aggregated 13F filings for Q1 2021.